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Abstract
Background—A common polymorphism, C776G, in the plasma B12 transport protein 
transcobalamin (TC), encodes for either proline or arginine at codon 259. This polymorphism may 
affect the affinity of TC for B12 and subsequent delivery of B12 to tissues.
Methods—TC genotype and its associations with indicators of B12 status, including total B12, 
holotranscobalamin (holoTC), methylmalonic acid, and homocysteine, were evaluated in a cohort 
of elderly Latinos (N=554, age 60–93y) from the Sacramento Area Latino Study on Aging 
(SALSA).
Results—The distribution of TC genotypes was 41.3% homozygous reference (776CC) and 
11.6% homozygous variant (776GG). No differences between the homozygous genotypes were 
observed in total B12, holoTC, methylmalonic acid, or homocysteine. The holoTC/total B12 ratio 
was lower in the 776GG group compared with the 776CC group (p=0.04). Significant interactions 
of TC genotype with total B12 (p=0.04) and with holoTC (p≤0.03) were observed such that mean 
homocysteine concentrations and the odds ratios for hyperhomocysteinemia (>13 µmol/L) were 
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higher in the 776CC subjects compared with all carriers of the G allele (776CG and 776GG 
combined) when total B12 (<156 pmol/L) or holoTC (<35 pmol/L) were low.
Conclusions—This population of older Latinos has a lower prevalence of the TC 776GG 
variant than reported for Caucasian populations. The association between vitamin B12 and 
homocysteine concentrations is modified by TC 776 genotype. It remains to be determined if the 
TC C776G polymorphism has a significant effect on the hematological and neurological 
manifestations of B12 deficiency or on vascular and other morbidities associated with 
hyperhomocysteinemia.
Keywords
Transcobalamin; polymorphism; homocysteine; vitamin B12; Hispanic elderly
INTRODUCTION
Vitamin B12 (B12) in plasma is bound to two distinct transport proteins, haptocorrin and 
transcobalamin (TC) (Chanarin, 1969; Green and Miller, 2007). Of these two proteins, only 
TC is known to play a role in both B12 absorption and cellular delivery. Dietary B12 is 
bound to TC in the ileal enterocyte and the TC-B12 complex (holoTC) enters the circulation. 
The circulating holoTC binds a specific TC receptor that is found on all tissues and is taken 
into the cell through endocytosis of the holoTC-receptor complex (Quadros et al., 2009). 
Thus, holoTC represents the fraction of total plasma B12 available for uptake into tissue. 
Accordingly, holoTC is considered to be a potential indicator of B12 status both 
independently and in conjunction with total B12 and other biochemical indicators of status 
(Ulleland et al., 2002; Refsum et al., 2006; Nexo et al., 2002; Herrmann et al., 2003; Miller 
et al., 2006; Garrod et al., 2008).
Several single nucleotide polymorphisms have been identified in the TC gene (gene 
designation: TCN2) (Li et al., 1994; Namour et al., 1998; Namour et al., 2001; Afman et al., 
2002). The most common is a cytosine-to-guanine substitution at base position 776 of the 
genomic DNA sequence (776C>G). This substitution encodes for arginine in place of 
proline at codon 259 of the amino acid sequence. It is unclear if this amino acid substitution 
affects the structure and function of the protein (Namour et al., 1998; Namour et al., 2001; 
Afman et al., 2002; Wuergas et al., 2006). The prevalence of the homozygous variant form 
of TC (776GG) is high, with reported estimates in different populations ranging from 3–
42% (Bowan et al., 2004; Gueant et al., 2007), which has led investigators to assess its 
influence on indicators of B12 status. Typically, no significant difference is found in total 
serum B12 concentrations among the TC 776 genotypes. In contrast, the 776GG variant has 
consistently been associated with lower serum or CSF levels of holoTC compared to the 
homozygous reference variant (776CC) (Afman et al., 2002; Wans et al., 2003; McCaddon 
et al., 2004; Zetterberg et al., 2003; von Castel-Dunwoody et al., 2005; Miller et al., 2002). 
The 776GG variant has also been associated with higher methylmalonic acid, a metabolite 
that becomes elevated in B12 deficiency (Miller et al., 2002; Fredriksen et al., 2007), a 
lower percentage of total B12 bound to TC (holoTC/B12 ratio) (Miller et al., 2002), and 
lower concentrations of TC with no B12 bound (apoTC) (Namour et al., 1998; Namour et 
al., 2001; Afman et al., 2002).
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Homocysteine, an independent risk factor for vascular disease and related disorders (Refsum 
et al., 1998), is elevated in B12 deficiency. It has been reported that individuals 
heterozygous for the TC 776 variant (776CG) have higher homocysteine concentrations than 
individuals homozygous for either the reference or variant forms (Namour et al., Namour 
and Gueant, 2001). This remains to be confirmed, however, and more typically no difference 
in homocysteine levels is observed among the TC genotypes (Afman et al., 2002; von 
Castel-Dunwoody et al., 2005; Miller et al., 2002; Fredriksen et al., 2007; McCaddon et al., 
2001; Zetterberg et al., 2002). A notable exception is the observation by Lievers et al. 
(2002) of a significant interaction between total B12 concentrations and TC genotype; the 
776CC reference was associated with lower total plasma homocysteine than the 776GG 
variant when total B12 was greater than 300 pmol/L. This suggests that the association 
between B12 concentration and homocysteine is modified by TC 776 genotype and that 
plasma homocysteine concentrations may be more responsive to dietary B12 or B12 
supplements in carriers of the 776CC reference compared with carriers of the 776GG 
variant.
In the present study, we examined associations between TC 776 genotype and indicators of 
B12 status in a cohort of community-dwelling older Hispanics participating in the 
Sacramento Area Latino Study on Aging (SALSA). We also determined if TC 776 genotype 
serves as an effect modifier of the associations between indicators of B12 status and 
homocysteine and methylmalonic acid concentrations.
MATERIALS AND METHODS
Subjects
The original SALSA study population consisted of a representative sample of community-
dwelling older adults (age ≥60y) of Latino ancestry residing in Sacramento, CA, and 
surrounding Northern California communities (n=1789). Subjects were recruited over a 
period of 18 months beginning in February 1998. The details of sampling and recruitment 
have been described elsewhere (Wu et al., 2002; Haan et al., 2003). Approximately five 
years after initial recruitment, additional blood samples were collected from 834 subjects 
and made available for genomic DNA isolation and genotyping. Of these 834, baseline 
holoTC and total B12 measures were available from 554 subjects for the present study. 
Subject recruitment and study procedures for the SALSA study were approved by the 
Human Subjects Review Committee at the University of California, Davis, and written 
informed consent was obtained from all study participants.
Sample Processing and Analysis
Fasting blood samples were collected from all subjects during home visits. The blood was 
transported on ice to the University of California Davis Medical Center Clinical Laboratory 
for processing within 4 h of collection. Plasma and serum were isolated and stored at −80 °C 
until analysis. Total plasma vitamin B12 concentrations were determined by radioassay 
Quantaphase II; BioRad Diagnostics, Hercules, CA); plasma holoTC by monoclonal 
antibody capture assay (HoloTC RIA; Axis-Shield, Oslo, Norway); plasma methylmalonic 
acid by tandem mass spectrometry at ARUP Laboratories, Salt Lake City, Utah (Kushnir et 
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al., 2001); total plasma homocysteine by HPLC with post-column fluorescence detection 
(Gilfix et al., 1997); red blood cell (RBC) folate by automated chemiluminescence assay 
(ACS 180: Chiron Diagnostics now Siemens Healthcare Diagnostics], Tarrytown, NY); and 
serum creatinine by the Jaffe rate reaction method using a SYNCHRON LX20 instrument 
(Beckman Coulter, Fullerton, CA). Inter-assay coefficients of variation for each of the 
assays are: total B12, 4.7%; holoTC, 5.7%; homocysteine, 4.2%; methylmalonic acid, 5.8%; 
RBC folate, 10%; and creatinine 3.3%. Cutoff values for low (deficient) or elevated plasma 
concentrations used in this study were: total B12 <156 pmol/L (reference value used by the 
UC Davis Medical Center Clinical Laboratory, Sacramento, CA, based on 100% specificity 
for clinically diagnosed B12 deficiency); holoTC <35 pmol/L (Herrmann et al., 2003; 
Lindgren et al., 1999); homocysteine >13 µmol/L (Jacques et al., 1999); and methylmalonic 
acid >350 nmol/L (Clarke et al., 2003).
DNA was isolated from EDTA whole blood using QIAamp DNA Blood Maxi Kits (Qiagen, 
Valencia, CA). TC 776 genotype was determined by polymerase chain reaction (PCR), 
using an Eppendorf Mastercycler (Brinkmann, Westbury, NY), and restriction enzyme 
digest as previously published (Miller et al., 2002). The PCR protocol was modified to 
shorten the assay time as follows: 1) bringing of lid temperature to 102 °C; 2) initial 
denaturation (94 °C, minutes); 3) 34 cycles of denaturation (94 °C, 1 minute), annealing (64 
°C, 1 minute), and extension (72 °C, 1 minute); 4) final extension (72 °C, 7 minutes).
Statistical Analyses
TC genotype and allele frequencies with Clopper-Pearson exact 95% confidence intervals 
were calculated. Chi-square analysis was used to determine if the TC genotypes were in 
Hardy-Weinberg equilibrium. Mean metabolite values were compared among the TC 
genotypes using Scheffe’s test. Sex distribution and percentage of subjects with low or high 
metabolite levels were compared among the TC genotypes by chi-square analysis. 
Interactive effects of TC genotype and total B12 (nominally divided into groups of < and 
≥156 pmol/L) and holoTC (nominally divided into groups < and ≥35 pmol/L) on 
homocysteine and methylmalonic acid levels were assessed by 2-factor ANOVA. Due to the 
small number of subjects in the 776GG group, the 776CG and 776GG genotypes were 
combined into one group and compared with the 776CC reference group for the 2-factor 
ANOVA. Because the distributions of homocysteine and methylmalonic acid did not 
conform to a Gaussian distribution (tailing toward higher values), these variables were 
natural log transformed before analysis. In secondary analyses, logistic regression was 
carried out to determine the odds ratios (95% C.I.) for elevated homocysteine (>13 µmol/L) 
for the 776CC group compared with the combined 776CG/776GG group, for total B12 <156 
pmol/L compared with total B12 ≥156 pmol/L, for holoTC <35 pmol/L compared with 
holoTC ≥35 pmol/L, and for the interactions between TC 776 genotype and total B12 or 
holoTC. For both the 2-factor ANOVA and logistic regression analyses, we controlled for 
confounding by age, sex, RBC folate, and creatinine. Statistical significance was defined as 
p<0.05.
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RESULTS
The characteristics of the study sample are presented in Table 1. The distribution of the TC 
polymorphism (with 95% C.I.) was: 776CC (homozygous reference), 41.3% (37.2, 45.6); 
776CG (heterozygotes), 47.1% (42.9, 51.4); and 776GG (homozygous variant), 11.6% (9.0, 
14.5). The allele frequencies (95% C.I.) for 776C and 776G were 0.65 (0.62, 0.68) and 0.35 
(0.32, 0.38), respectively. The distribution is within Hardy-Weinberg equilibrium (X2=0.64, 
p=0.42). No significant difference in total B12 was observed among the genotypes. Mean 
holoTC in the 776GG group was lower than in the 776CC group, but the difference did not 
reach statistical significance (p=0.09). The difference in mean holoTC/B12 ratio was, 
however, significantly lower in the 776GG group compared with the 776CC group (p=0.01). 
There were no significant differences in homocysteine or methylmalonic acid levels among 
the genotypes, nor were there significant differences among the genotypes in percentages of 
subjects with low total B12 (<156 pmol/L), low holoTC (<35 pmol/L), high methylmalonic 
acid (>350 nmol/L), or high homocysteine (>13 µmol/L).
By 2-factor ANOVA, significant interactions between TC genotype and total B12 (p=0.04) 
and between TC genotype and holoTC (p=0.02) on homocysteine were observed. 
Subsequent analyses for subjects divided by low and high total B12 (< or ≥156 pmol/L) 
revealed that homocysteine was higher in the 776CC group compared with the combined 
776CG/776GG group for those subjects with low total B12, though the difference did not 
reach statistical significance (p=0.08). No difference was observed in homocysteine between 
the genotype groups for subjects with high total B12 (Figure 1). For subjects divided by low 
and high holoTC (< or ≥35 pmol/L), homocysteine was significantly higher in the 776CC 
group compared with the combined 776CG/776GG group for those subjects with low 
holoTC (p=0.02), while no difference was observed between the genotype groups for 
subjects with high holoTC (Figure 2). No significant interactive effects were observed 
between TC genotype and either total B12 or holoTC on methylmalonic acid concentrations 
(data not shown).
Multivariate logistic regression analyses were performed to assess the risk of having 
hyperhomocysteinemia (>13 µmol/L) between the TC 776 genotype groups, between 
subjects with low and high total B12 or low and high holoTC, and for the interaction 
between TC 776 genotype and total B12 or holoTC. For the model including low and high 
total B12 as an independent variable (Table 2, Model 1), the interaction between genotype 
and total B12 was significant (p=0.04), and subjects with low total B12 (p<0.001) or who 
were homozygous for the 776CC reference (p=0.05) had elevated odds ratios for 
hyperhomocysteinemia. Similarly, for the model including low and high holoTC as an 
independent variable (Table 2, Model 2), the interaction between genotype and holoTC was 
significant (p=0.03), and subjects with low total holoTC (p<0.001) or who were 
homozygous for the 776CC reference (p=0.03) had elevated odds ratios for 
hyperhomocysteinemia.
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DISCUSSION
The prevalence of the homozygous TC 776GG variant in the SALSA study sample was 
11.6%, compared to 17.6% in a group of 239 Hispanic blood donors from the Mexico City 
area (Gueant et al., 2007). The reason for the difference in prevalence between these two 
study samples of the same ethnicity is unclear, but the latter study included subjects age 20–
60y, while in SALSA they were ≥60y. In addition, it is not known whether these Hispanic 
cohorts are genetically similar. Reported prevalence of the 776GG variant in other ethnic 
groups ranges from ~3% in West Africans to ~11% in Italian Caucasians; ~13% in Afro-
Americans; ~13% in Brazilians; ~20% in French, Scandinavian, and American Caucasians; 
and ~42% in ethnic Hans from Central China (Bowen et al., 2004; Gueant et al., 2007; 
Miller et al., 2002; Bottiger and Nilsson et al., 2007; Pereira et al., 2007; Alessio et al., 
2007). Gueant et al. (2007) have proposed that environmental factors, in particular malaria, 
may have imposed selective pressures that contribute to the wide variation in prevalence of 
the TC 776 polymorphism in different populations.
There was no difference among the genotypes in total B12 concentration, consistent with 
previous reports (Namour et al., 2001; Zetterberg et al., 2003; von Castel-Dunwoody et al., 
2005; Miller et al., 2002; McCaddon et al., 2001; Zetterberg et al., 2002). HoloTC was 
lower in the 776GG homozygous variant group, also consistent with reports by others 
(Afman et al., 2002; Wans et al., 2003; McCaddon et al., 2004; Zetterberg et al., 2003; von 
Castel-Dunwoody et al., 2005; Miller et al., 2002), although the difference in the SALSA 
study sample did not reach statistical significance. There was a significant difference among 
the genotypes in holoTC/B12 ratio, an observation we made previously in a study of 
primarily Caucasian individuals (Miller et al., 2002). It has been proposed that the TC 776 
polymorphism may affect the intra-molecular folding of the transcobalamin protein resulting 
in reduced affinity for B12, though there is some disagreement on this issue (Namour et al., 
1998; Namour et al., 2001; Afman et al., 2002; Wuergas et al., 2006). The lower 
holoTC/B12 ratio observed in individuals with the 776GG homozygous variant suggests that 
the G allele may indeed encode a protein with a significantly lower affinity for B12 than that 
encoded by the C allele. This may have important clinical implications based on our 
published finding that the holoTC/B12 ratio is associated with cognitive impairment in the 
SALSA population, particularly in those with elevated depressive symptoms (Garrod et al., 
2008). A possible influence of TC genotype on the binding of holoTC to the TC receptor is 
also a potential consideration. This may now be investigated since the TC receptor has been 
cloned recently (Quadros et al., 2009).
The most novel findings in this study are the significant interactions between TC genotype 
and indicators of B12 status (total B12 and holoTC) on homocysteine concentrations. 
Differences in homocysteine were observed between the genotypes only in those subjects 
with low total B12 or low holoTC. Mean homocysteine concentrations and odds ratios for 
hyperhomocysteinemia were higher for 776CC homozygotes compared with carriers of the 
G allele (776CG and 776GG combined) when total B12 or holoTC were low. Lievers et al. 
(2002) made a similar, though not identical observation: individuals homozygous for the 
reference allele with total B12 ≥300 pmol/L had lower homocysteine than those with the 
variant allele. An interaction between TC genotype and holoTC on homocysteine, however, 
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was not assessed in this study (Lievers et al., 2002). Together these findings suggest that TC 
776 genotype is an effect modifier of the association between B12 status and homocysteine 
concentration, and that in those homozygous for the C allele, homocysteine levels may be 
more responsive to dietary B12 or B12 supplementation than in those with one or two G 
alleles. This may be an important consideration when evaluating the effect of B12 
supplements or other modes of B12 intervention on plasma homocysteine. It is also 
important to note that since higher homocysteine was observed in the 776CC reference 
group when B12 status was low, the influence of the polymorphism on homocysteine levels 
may be more complicated than simply reduced affinity of TC for B12 caused by the 
presence of the G allele, as discussed above. It could be argued that the G allele is actually 
protective rather than deleterious when B12 status is low, which perhaps explains the 
relatively high prevalence of the variant form observed in different populations.
No significant difference was observed in methylmalonic acid concentrations among the TC 
genotypes, nor was a significant interaction detected between TC genotype and total B12 or 
holoTC on methylmalonic acid. This differs from our previous study in which we observed 
higher methylmalonic acid concentrations in the TC 776GG homozygotes compared with 
the TC 776CC homozygotes (Miller et al., 2002). This discrepancy between the two studies 
may be due to genetic, dietary or other environmental differences between Caucasian and 
Hispanic populations.
The influence of the TC 776 polymorphism on risk of clinical B12 deficiency remains to be 
determined. There are reports of direct associations between the 776 G allele and neural tube 
defects (Pietrzyk and Bik-Multanowski, 2003; Gueant-Rodriguez et al., 2003), spontaneous 
abortion (Zetterberg et al., 2002), cleft palate/lip (Martinelli et al., 2006), and autism (James 
et al., 2006). Other studies did not confirm the associations with neural tube defects and 
spontaneous abortion (Afman et al., 2002; Swanson et al., 2005; Brouns et al., 2008; Parle-
McDermott et al., 2005). One report found that TC genotype may influence the age of onset 
of Alzheimer’s disease (McCaddon et al., 2004). TC genotype was not associated with 
congenital heart defects (Verkleij-Hagoort et al., 2008) and thrombosis (Zetterberg et al., 
2002; Pereira et al., 2007). Notably, in none of these studies was the interaction between TC 
genotype and indicators of B12 status (i.e. total B12 or holoTC) on clinical risk considered. 
TC genotype might be an effect modifier of the associations between markers of B12 status 
and clinical disorders, as suggested by our finding of a significant interaction between 
holoTC and TC genotype on homocysteine concentrations in the SALSA study.
A final consideration is that our present findings were made in a population exposed to folic 
acid fortification, fully implemented in the United States as of January 1998 with the 
purpose of reducing the incidence of neural tube defects. We have shown elsewhere that in 
the SALSA study sample the prevalence of folate deficiency is very low (~1%) and that 
vitamin B12 status is now the dominant nutritional determinant of homocysteine levels 
(Green and Miller, 2005), at least in older adults. The present study suggests that in a folic 
acid fortified population, TC 776 genotype is an effect modifier of the associations between 
total B12 or holoTC concentrations and the risk of hyperhomocysteinemia, a condition 
which is associated with vascular disorders, cognitive dysfunction and dementia, birth 
defects, and osteoporosis Refsum et al., 1998, Selhub, 2008).
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Figure 1. 
Interaction between total B12 and transcobalamin genotype on homocysteine. ANOVA for 
interaction between TC genotype (grouped as 776 CC and 776CG + 776GG) and total B12 
(grouped as < and ≥ 156 pmol/L) was significant (p=0.04). Post-hoc comparisons of group 
means were made using Scheffe’s test, with controlling for age, sex, red blood cell folate, 
and creatinine. Bars represent geometric means with 95% confidence intervals.
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Figure 2. 
Interaction between holotranscobalamin (holoTC) and TC genotype on homocysteine. 
ANOVA for interaction between TC genotype (grouped as 776 CC and 776CG + 776GG) 
and holoTC (grouped as < and ≥ 35 pmol/L) was significant (p=0.02). Post-hoc comparisons 
of group means were made using Scheffe’s test, with controlling for age, sex, red blood cell 
folate, and creatinine. Bars represent geometric means with 95% confidence intervals.
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Table 1
Characteristics of study sample grouped by transcobalamin 776 genotype*
TC 776 Genotype
All Subjects CC CG GG
N 554 229 261 64
  Frequency % (95% C.I.) 41.3 (37.2, 45.6) 47.2 (42.9, 51.4) 11.6 (9.0, 14.5)
Sex (% female) 60 63 57 64
Age (y) 69 ± 6 69 ± 6 70 ± 6 69 ± 6
Vitamin B12 (pmol/L) 314 ± 128 316 ± 142 312 ± 121 316 ± 107
  B12 <156 pmol/L (%) 8.5 9.6 7.7 7.8
HoloTC (pmol/L) 78 ± 32 80 ± 33 77 ± 33 70 ± 27
  HoloTC <35 pmol/L (%) 8.5 8.3 9.6 4.7
HoloTC/B12 Ratio (%) 25.7 ± 0.1 26.5 ± 0.1 25.6 ± 0.1 22.8 ± 0.1**
MMA (nmol/L) 239 ± 562 286 ± 841 204 ± 182 207 ± 134
  MMA >350 (%) 10.3 10.4 9.0 16.7
Hcy (μmol/L) 10.4 ± 6.4 10.8 ± 9.1 10.2 ± 3.3 9.7 ± 3.3
  Hcy >13 μmol/L (%) 12.3 12.7 12.6 9.4
RBC Folate (ng/mL) 509 ± 157 505 ± 153 513 ± 160 509 ± 158
Creatinine (mg/dL) 0.8 ± 0.3 0.8 ± 0.3 0.8 ± 0.2 0.8 ± 0.2
*Values are means ± SD, except for N, frequency, sex, and percentage below or above cutoff values.
**Significantly different from 776CC group by Scheffe’s test (p=0.04).
Abbreviations: TC, transcobalamin; HoloTC, holotranscobalamin; MMA, methylmalonic acid; Hcy, homocysteine; RBC, red blood cell.
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Table 2
Odds ratios for elevated homocysteine (>13 μmol/L)**
Model OR (95% C.I.) p-value
Model 1:
 776CC vs 776CG+776GG 18.8 (1.04, 339) 0.05
 Total B12 <156 vs ≥156 pmol/L 220 (14.7, 3310) <0.001
 TC Genotype * Total B12 5.41 (1.08, 27.0) 0.04
Model 2:
 776CC vs 776CG+776GG 27.9 (1.33, 584) 0.03
 HoloTC <35 vs ≥35 pmol/L 227 (13.7, 3760) <0.001
 TC Genotype * HoloTC 5.99 (1.14, 31.6) 0.03
**Odds ratios and 95% confidence intervals were calculated controlling for confounding by age, sex, red blood cell folate, and creatinine.
Abbreviations: OR, odds ratio; C.I., confidence interval; TC, transcobalamin; HoloTC, holotranscobalamin; 776CC, transcobalamin homozygous 
wild-type; 776CG, transcobalamin heterozygotes; 776GG, transcobalamin homozygous variant.
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